WUHAN AND BIODELTA FORM INTERNATIONAL JOINT VENTURE - To launch Dr AnnaRx CBD Products in 1000 Pharmacies Across SA
31 January 2019 - 12:21AM
InvestorsHub NewsWire
WUHAN AND
BIODELTA
FORM INTERNATIONAL JOINT
VENTURE
To launch Dr. AnnaRx CBD
Products in 1000 Pharmacies Across SA
Los Angeles, CA --
January 30,
2019 --
InvestorsHub NewsWire -- Wuhan General Group (China),
Inc. (OTC
PINK: WUHN) (the "Company" and "Wuhan"), announced today that
its wholly-owned subsidiary
MJ MedTech, Inc. (MJ
MedTech) and Biodelta Nutraceuticals, Ltd.
(Biodelta) have entered into a joint venture to
develop, brand, market and commercialize the internationally
trademarked Dr. AnnaRx.
The joint venture calls for an
initial pilot whereby the Dr. AnnaRx line of CBD based products will
be sold (as regulations allow) across South Africa in more than
1,000 pharmacies. The data Biodelta collects on the pilot will
enable them to ensure the Dr. AnnaRx brand will deliver the highest
possible ROI when introduced internationally.
This partnership marks a very
strong start to 2019 for MJ MedTech as the Company expects to have
product on the shelves by Q2/3 of 2019.
Dr. Anna Leralta, CMO
of
Wuhan,
commented, "I'm thrilled to be working with the very strong
scientific team at Biodelta. They have proven for many
years their outstanding track record and expertise in the field of
science-backed nutraceuticals. They are an ideal partner to help
support our vision of developing effective CBD products backed by
sound science."
Under the terms of the
Agreement, Biodelta will exclusively develop,
distribute and merchandise all products sold under the Dr.
AnnaRx
brand in South
Africa and 8 additional African countries across the African
continent.
Leon Giese, CEO of
Biodelta
added "There is a
growing demand for CBD products in the South African market.
Retailers and consumers want a brand they can trust, and we believe
Dr. AnnaRx is a perfect
fit".
About
Biodelta
Nutraceuticals
Biodelta Nutraceuticals (ISO 22000 and
organic certified) is a Cape Town based Manufacturer and
Merchandiser of premium health products to all pharmacy &
health shop chains across South Africa. For the past 12
years, Biodelta has developed, designed and
produced more than 1000 products for these customers and is now
strategically positioned to launch CBD products through these
channels. In addition, Biodelta has license applications in
process for growing, extracting and product development as well as
dossiers for various CBD based products.
For further information
contact:
Website: https://biodelta.net/
Public Relations
E-mail: info@biodelta.net
About Wuhan General Group
(China), Inc.
Wuhan General Group (China),
Inc. through its wholly-owned subsidiary MJ MedTech is a
nutraceutical biotechnology company that owns, develops and
commercializes a range of CBD-based products. At Wuhan, our mission
is to advance CBD-based medicine to the forefront by deploying best
practice science and medicine, clinical research and emerging
technologies.
For further information
contact:
Publicly traded company
(OTC
Pink: WUHN)
Website: www.wuhn.org
Public Relations E-mail:
info@wuhn.org
Forward-Looking
Statements:
Safe Harbour Statement - In
addition to historical information, this press release may contain
statements that constitute forward-looking statements within the
meaning of the Securities Act of 1933 and the Securities Exchange
Act of 1934, as amended by the Private Securities Litigation Reform
Act of 1995. Forward-looking statements contained in this press
release include the intent, belief, or expectations of the Company
and members of its management team with respect to the Company's
future business operations and the assumptions
upon which such statements are based. Prospective investors are
cautioned that any such forward-looking statements are not
guarantees of future performance, and involve risks and
uncertainties and that actual results may differ materially from
those contemplated by such forward-looking statements. Factors that
could cause these differences include, but are not limited to,
failure to complete anticipated sales under negotiations, lack of
revenue growth, client discontinuances, failure to realize
improvements in performance, efficiency and profitability, and
adverse developments with respect to litigation or increased
litigation costs, the operation or performance of the Company's
business units or the market price of its common stock. Additional
factors that could cause actual results to differ materially from
those contemplated within this press release can also be found on
the Company's website. The Company disclaims any responsibility to
update any forward-looking statements.
Source: Wuhan General Group
(China), Inc.
Wuhan General (CE) (USOTC:WUHN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Wuhan General (CE) (USOTC:WUHN)
Historical Stock Chart
From Dec 2023 to Dec 2024
